Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Arginetix on Series A Financing


WASHINGTON, DC, October 2, 2009 — Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The financing was co-led by Quaker BioVentures and MedImmune Ventures, the latter a wholly owned venture capital fund of the AstraZeneca Group. Maryland Heath Care Product Development Corp., Osage University Partners, Red Abbey Venture Partners, and company co-founder Acidophil LLC also participated in the round. Covington & Burling LLP represented Arginetix, Inc. on the transaction.

Arginetix will utilize this financing for further discovery and to continue development of its first-in-class arginase inhibitors for cardiovascular and pulmonary indications. The company's scientific foundation is based on licensed intellectual property of its scientific co-founders, David Christianson, Ph.D. at the University of Pennsylvania and Dan Berkowitz, M.D. at The Johns Hopkins University.

The Covington corporate team was led by Washington-based partner Doug Gibson and associate Heather Davis.

Share this article: